艾塞那肽住院管理2型糖尿病的安全性和有效性随机对照试验
这项多中心开放标签随机试验纳入150例非危重住院的2型糖尿病患者,随机分为艾塞那肽单药、艾塞那肽联合基础胰岛素或基础-餐时胰岛素方案。结果显示,艾塞那肽联合基础胰岛素与基础-餐时方案的平均每日血糖相似,且低血糖和住院时长无差异,提示艾塞那肽单用或联合基础胰岛素对住院患者安全有效。
要点
- 艾塞那肽联合基础胰岛素与基础-餐时方案的平均每日血糖相似,且目标范围内血糖比例更高。
- 艾塞那肽单用或联合基础胰岛素未增加低血糖风险,但恶心呕吐较基础-餐时方案更常见。
- 该方案可用于非危重住院的2型糖尿病患者,但需注意胃肠道不良反应。
核心结论
- 艾塞那肽单用或联合基础胰岛素对住院的非危重内科和外科2型糖尿病患者安全有效。
研究设计与样本
- 多中心、开放标签、随机对照试验,纳入150例血糖在140至400 mg/dL之间的非危重住院2型糖尿病患者。
主要发现
- 艾塞那肽联合基础胰岛素组与基础-餐时组的平均每日血糖相似(154 ± 39 vs. 166 ± 40 mg/dL,P = 0.31)。
- 艾塞那肽联合基础胰岛素组的平均每日血糖低于艾塞那肽单药组(177 ± 41 mg/dL,P = 0.02)。
- 艾塞那肽联合基础胰岛素组血糖在70至180 mg/dL目标范围内的比例高于艾塞那肽单药组和基础-餐时组(78% vs. 62% vs. 63%,P = 0.023)。
- 艾塞那肽单药组和联合基础胰岛素组的恶心或呕吐发生率分别为10%和11%,高于基础-餐时组的2%(P = 0.17),有3例(6%)因不良事件停用艾塞那肽。
- 三组间低血糖<54 mg/dL的发生率(2% vs. 0% vs. 4%,P = 0.77)和住院时长(5 vs. 4 vs. 4天,P = 0.23)无差异。
临床怎么用
- 对于非危重住院的2型糖尿病患者,可考虑使用艾塞那肽单用或联合基础胰岛素控制血糖。
- 使用艾塞那肽时需监测恶心、呕吐等胃肠道不良反应,必要时停药。
局限性
- 本研究为预试验,样本量较小,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This multicenter, open-label, randomized trial examined the safety and efficacy of exenatide alone or in combination with basal insulin in non-critically ill patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: A total of 150 patients with blood glucose (BG) between 140 and 400 mg/dL, treated at home with diet, oral agents, or insulin at a total daily dose <0.5 units/kg, were randomized to exenatide alone (5 μg twice daily), exenatide plus basal insulin, or a basal-bolus insulin regimen. The primary end point was difference in mean daily BG concentration among groups. RESULTS: Mean daily BG was similar between patients treated with exenatide plus basal and a basal-bolus regimen (154 ± 39 vs. 166 ± 40 mg/dL, P = 0.31), and exenatide plus basal resulted in lower daily BG than did exenatide alone (177 ± 41 mg/dL, P = 0.02). Exenatide plus basal resulted in a higher proportion of BG levels in target range between 70 and 180 mg/dL compared with exenatide and basal-bolus (78% vs. 62% vs. 63%, respectively, P = 0.023). More patients in the exenatide and exenatide plus basal groups experienced nausea or vomiting than in the basal-bolus group (10% vs. 11% vs. 2%, P = 0.17), with three patients (6%) discontinued exenatide owing to adverse events. There were no differences in hypoglycemia <54 mg/dL (2% vs. 0% vs. 4%, P = 0.77) or length of stay (5 vs. 4 vs. 4 days, P = 0.23) among basal plus exenatide, exenatide, and basal-bolus groups. CONCLUSIONS: The results of this pilot study indicate that exenatide alone or in combination with basal insulin is safe and effective for the management of hospitalized general medical and surgical patients with T2D.
引用
- Fayfman M, Galindo RJ, Rubin DJ, et al. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 30679302. doi:10.2337/dc18-1760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。